BRCA2 PVs are associated with a more aggressive PCa phenotype than BRCA1 PVs [11, 12, 20, 23, 46], and the results may hence reflect that BRCA2 carriers are more likely than BRCA1 carriers to have clinically significant PCa which is diagnosed regardless of screening. The gene discussed is BRCA2; the disease is posterior cortical atrophy.